Seeking Alpha

Canaccord says Momenta Pharmaceuticals (MNTA +1.3%) risk/reward looks favorable going into the...

Canaccord says Momenta Pharmaceuticals (MNTA +1.3%) risk/reward looks favorable going into the generic Copaxone suit - which is expected to be resolved in H212. Canaccord thinks consensus is only factoring in a 25% chance of a win for MNTA and its sees more upside potential.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs